08/26/2026
The drug companies Merck and Moderna, Inc. have announced a successful late-stage trial for a personalized mRNA vaccine designed to help prevent the return and spread of melanoma, opening a new avenue of treatment that doctors hope will work against many types of tumors.
"We should be hearing results from multiple studies over the next few years, and there's every reason to hope now, with this news, that many of them will be positive," said Robert Vonderheide, MD, DPhil, director of the Abramson Cancer Center and president-elect of the American Association for Cancer Research (AACR).
NPR